Rein Therapeutics, Inc. (RNTX): Shareholders' Equity
$16.92M
As of 2025-12-31
$55.20M
As of 2026-06-30
-3.1%
3-year compound annual growth
+6.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.92M | -68.9% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $54.39M | -44.7% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $98.30M | +427.8% | 2025-04-07, Balance as of period end |
| 2022-12-31 | $18.62M | -57.6% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $43.90M | +261.0% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $12.16M | -24.2% | 2023-03-20, Balance as of period end |
| 2019-12-31 | $16.05M | -18.1% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $19.60M | -59.0% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $47.80M | n/m | 2019-03-29, Balance as of period end |
| 2016-12-31 | -$111.81M | n/m | 2018-04-02, Balance as of period end |
| 2015-12-31 | -$94.32M | n/a | 2018-04-02, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $16.92M | -68.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare RNTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗